trial
as of 2026-07-0120101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
NCTId NCT01568216
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Terminated
Enrollment
121 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-05
Primary completion
2013-06
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Drugs
Indications
Sponsors
AmgenLead Sponsor
Sites
38 total
Anaheim, United StatesCerritos, United StatesCulver City, United StatesGarden Grove, United StatesLos Angeles, United StatesNorwalk, United StatesSan Bernardino, United StatesTorrance, United StatesWashington D.C., United StatesNorth Miami, United StatesAtlanta, United StatesChicago, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
121
Phase
PHASE2
Primary Completion Date
2013-06
Status
TERMINATED
relationships
The graph out of here